Show simple item record

dc.contributor.authorDavies, MM
dc.contributor.authorMathur, P
dc.contributor.authorCarnochan, P
dc.contributor.authorSaini, S
dc.contributor.authorAllen-Mersh, TG
dc.date.accessioned2018-09-18T14:44:22Z
dc.date.issued2002-01-07
dc.identifier1
dc.identifier.citationBRITISH JOURNAL OF CANCER, 2002, 86 pp. 123 - 129
dc.identifier.issn0007-0920
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2798
dc.identifier.doi10.1038/sj.bjc.6600020
dc.description.abstractOne explanation for the clinical association between tumour vascularity and probability of metastasis is that increased primary tumour vascularity enhances haematogenous dissemination by offering greater opportunity for tumour cell invasion into the circulation (intravasation). We devised an experimental tumour metastasis model that allowed manipulation of primary tumour vascularity with differential exposure of the primary and metastatic tumour site to angiogenic agents. We used this model to assess the effects of local and systemic increases in the level of the angiogenic agent basic fibroblast growth factor on metastasis. BDIX rats with implanted hind limb K12/TR adenocarcinoma tumours received either intratumoural or systemic, basic fibroblast growth factor or saline infusion. Both intratumoural and systemic basic fibroblast growth factor infusion resulted in significant increases in tumour vascularity, blood flow and growth, but not lung metastasis, compared with saline-infused controls. Raised basic fibroblast growth factor levels and increase in primary tumour vascularity did not increase metastasis. The clinical association between tumour vascularity and metastasis is most likely to arise from a metastatic tumour genotype that links increased tumour vascularity with greater metastatic potential.
dc.format.extent123 - 129
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.titleEffect of manipulation of primary tumour vascularity on metastases in an adenocarcinoma model
dc.typeJournal Article
rioxxterms.versionofrecord10.1038/sj.bjc.6600020
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2002-01-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBRITISH JOURNAL OF CANCER
pubs.notesunique-id: ISI:000174150200023
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.volume86
pubs.embargo.termsNot known
dc.contributor.icrauthorCarnochan, Paul


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record